
Balchem Corporation
NASDAQ•BCPC
CEO: Mr. Theodore L. Harris
Sector: Basic Materials
Industry: Chemicals - Specialty
Listing Date: 1986-06-03
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
Contact Information
Market Cap
$5.07B
P/E (TTM)
34.3
28.2
Dividend Yield
0.6%
52W High
$177.40
52W Low
$139.17
52W Range
Rank23Top 6.9%
6.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$267.56M+11.51%
4-Quarter Trend
EPS
$1.25+20.19%
4-Quarter Trend
FCF
$50.67M+20.20%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Net Sales Growth Strong Nine months net sales reached $773.544M, growing 8.4%. HNH segment sales grew 8.9% driven by volume and pricing.
Net Earnings Jump 21.8% Nine months net earnings totaled $115.620M, marking a substantial 21.8% increase year-over-year comparison. Operating margin improved to 20.3%.
Operating Cash Flow Rises Cash provided by operating activities was $149.281M for nine months, increasing 15.1%. Investing activities used $27.475M.
Interest Expense Significantly Lower Nine months net interest expense decreased 39.3% to $8.319M due to lower outstanding borrowings under the 2022 Credit Agreement.
Risk Factors
Raw Material Input Costs Gross margin improvement partially offset by certain higher manufacturing input costs across nine months results comparison.
Foreign Currency Exchange Risk Exposure exists due to foreign subsidiaries' operations; currency fluctuations impact reported financial condition and results translation.
EU Anti-Dumping Duties Pending Provisional duties imposed on choline chloride imports from China; final measures expected by year-end 2025 impacting operations.
Litigation and Contingencies Exposure Ongoing involvement in various lawsuits, including Superfund site remediation liabilities at the Verona, Missouri facility.
Outlook
Focus on Productivity Enhancements Management plans to leverage existing technology capabilities to optimize productivity and performance, driving efficiencies moving forward.
Active Acquisition Candidate Pursuit Company actively pursuing additional acquisition candidates; may seek additional bank loans or access financial markets if needed.
Capital Structure Management Repurchase program remains active; intends to acquire shares based on cash flow assessment and market conditions.
New Accounting Standard Adoption Evaluating impact of recently issued ASU 2024-03 regarding comprehensive income expense disaggregation disclosures.
Peer Comparison
Revenue (TTM)
SSL$28.48B
$9.71B
AXTA$5.17B
Gross Margin (Latest Quarter)
58.3%
ESI42.2%
BCPC35.7%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| AXTA | $7.13B | 15.5 | 21.3% | 0.3% |
| ESI | $6.17B | 25.7 | 9.4% | 32.2% |
| BCPC | $5.07B | 34.3 | 12.1% | 9.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.7%
Moderate Growth
4Q Net Income CAGR
6.3%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Feb 20, 2026
EPS:$1.29
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Oct 21, 2025|Revenue: $267.56M+11.5%|EPS: $1.25+20.2%BeatForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Jul 31, 2025|Revenue: $255.47M+9.1%|EPS: $1.18+19.2%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: Apr 24, 2025|Revenue: $250.52M+4.5%|EPS: $1.14+26.7%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 21, 2025|Revenue: $953.68M+3.4%|EPS: $3.97+17.5%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 25, 2024|Revenue: $239.94M+4.3%|EPS: $1.04+14.3%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Jul 26, 2024|Revenue: $234.08M+1.2%|EPS: $0.99+5.3%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 3, 2024|Revenue: $239.66M+3.1%|EPS: $0.90+26.8%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 16, 2024|Revenue: $922.44M-2.1%|EPS: $3.38+2.7%Beat